The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis.

IF 1.3 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Journal of Pediatric Endocrinology & Metabolism Pub Date : 2024-01-19 Print Date: 2024-03-25 DOI:10.1515/jpem-2023-0480

Na Guo, Fei Zhou, Xiaolan Jiang, Linlin Yang, Huijuan Ma

{"title":"The effect of gonadotropin-releasing hormone analog treatment on the endocrine system in central precocious puberty patients: a meta-analysis.","authors":"Na Guo, Fei Zhou, Xiaolan Jiang, Linlin Yang, Huijuan Ma","doi":"10.1515/jpem-2023-0480","DOIUrl":null,"url":null,"abstract":"Objectives: Gonadotropin-releasing hormone (GnRHa) is the first choice for the treatment of patients with central precocious puberty (CPP). However, the effects of GnRHa on the endocrine system of CPP patients, including insulin sensitivity, lipid level, thyroid function, bone mineral density (BMD), and testosterone (T) level, are currently contradictory. Therefore, the long-term safety of GnRHa therapy remains controversial.Content: A systematic literature search was performed using PubMed, Embase, Cochrane Library, and CNKI databases. The changes in HOMA-IR, TG, LDL-C, HDL-C, TSH, FT3, FT4, T, and BMD in CPP patients before and after GnRHa treatment were compared by meta-analysis. As the heterogeneity between studies, we estimated standard deviation mean differences (SMDs) and 95 % confidence intervals (CIs) using a random-effects model. Egger's test was used to assess publication bias.Summary: A total of 22 studies were included in our meta-analysis. Compared with before GnRHa treatment, there were no statistically significant differences in endocrine indicators including HOMA-IR, TG, LDL-C, HDL-C, TSH, FT4, FT3, T, and BMD of CPP patients treated with GnRHa.Outlook: Treatment with GnRHa for central precocious puberty will not increase the adverse effect on the endocrine system.","PeriodicalId":50096,"journal":{"name":"Journal of Pediatric Endocrinology & Metabolism","volume":" ","pages":"197-208"},"PeriodicalIF":1.3000,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Endocrinology & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/jpem-2023-0480","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/25 0:00:00","PubModel":"Print","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Gonadotropin-releasing hormone (GnRHa) is the first choice for the treatment of patients with central precocious puberty (CPP). However, the effects of GnRHa on the endocrine system of CPP patients, including insulin sensitivity, lipid level, thyroid function, bone mineral density (BMD), and testosterone (T) level, are currently contradictory. Therefore, the long-term safety of GnRHa therapy remains controversial.

Content: A systematic literature search was performed using PubMed, Embase, Cochrane Library, and CNKI databases. The changes in HOMA-IR, TG, LDL-C, HDL-C, TSH, FT3, FT4, T, and BMD in CPP patients before and after GnRHa treatment were compared by meta-analysis. As the heterogeneity between studies, we estimated standard deviation mean differences (SMDs) and 95 % confidence intervals (CIs) using a random-effects model. Egger's test was used to assess publication bias.

Summary: A total of 22 studies were included in our meta-analysis. Compared with before GnRHa treatment, there were no statistically significant differences in endocrine indicators including HOMA-IR, TG, LDL-C, HDL-C, TSH, FT4, FT3, T, and BMD of CPP patients treated with GnRHa.

Outlook: Treatment with GnRHa for central precocious puberty will not increase the adverse effect on the endocrine system.

查看原文本刊更多论文

促性腺激素释放激素类似物治疗对中枢性性早熟患者内分泌系统的影响：一项荟萃分析。

目的：促性腺激素释放激素（GnRHa促性腺激素释放激素（GnRHa）是治疗中枢性性早熟（CPP）患者的首选药物。然而，GnRHa 对 CPP 患者内分泌系统（包括胰岛素敏感性、血脂水平、甲状腺功能、骨矿物质密度（BMD）和睾酮（T）水平）的影响目前尚存在矛盾。因此，GnRHa疗法的长期安全性仍存在争议：内容：使用 PubMed、Embase、Cochrane Library 和 CNKI 数据库进行了系统性文献检索。通过荟萃分析比较了GnRHa治疗前后CPP患者的HOMA-IR、TG、LDL-C、HDL-C、TSH、FT3、FT4、T和BMD的变化。由于研究之间存在异质性，我们采用随机效应模型估算了标准差均值（SMD）和 95 % 置信区间（CI）。总结：我们的荟萃分析共纳入了 22 项研究。与GnRHa治疗前相比，接受GnRHa治疗的CPP患者的HOMA-IR、TG、LDL-C、HDL-C、TSH、FT4、FT3、T和BMD等内分泌指标均无统计学差异：展望：使用GnRHa治疗中枢性性早熟不会增加对内分泌系统的不良影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Pediatric Endocrinology & Metabolism 医学-内分泌学与代谢

CiteScore

2.70

自引率

7.10%

发文量

176

审稿时长

3-6 weeks

期刊介绍： The aim of the Journal of Pediatric Endocrinology and Metabolism (JPEM) is to diffuse speedily new medical information by publishing clinical investigations in pediatric endocrinology and basic research from all over the world. JPEM is the only international journal dedicated exclusively to endocrinology in the neonatal, pediatric and adolescent age groups. JPEM is a high-quality journal dedicated to pediatric endocrinology in its broadest sense, which is needed at this time of rapid expansion of the field of endocrinology. JPEM publishes Reviews, Original Research, Case Reports, Short Communications and Letters to the Editor (including comments on published papers),. JPEM publishes supplements of proceedings and abstracts of pediatric endocrinology and diabetes society meetings.